Hochaktiv und den Bedürfnissen der Patienten angepasst - Individualisierte Therapie der HIV-Infektion

Zusammenfassung

Die antiretrovirale Therapie von HIV-infizierten Personen hat sich in den letzten Jahren durch die Einführung einer zunehmenden Zahl von verschiedenen Substanzen und Substanzklassen deutlich verbessert. Diese Entwicklung erlaubt nicht nur eine hochaktive antiretrovirale Therapie („highly active anti-retroviral therapy”, HAART), die auf einer Kombination von verschiedenen Substanzen basiert, sondern ermöglicht auch eine Anpassung der antiretroviralen Medikamente an das Nebenwirkungsprofil und die individuellen Bedürfnisse der Patienten. Die Resistenztestung hilft bei der Auswahl der optimalen Therapiestrategie. Die Überwachung der Therapie erfolgt über die Bestimmung der CD4⁺-Zellen und der Menge an HIV im Blut.

Summary

Antiretroviral treatment of HIV infected individuals has significantly improved within the recent years by introduction of an increasing number of different drugs and drug classes. This development allows not only a „highly active antiretroviral therapy” (HAART), based on combination of different drugs, but also an adaptation of the antiretroviral medicaments according to the drug toxicity profile and the individual patient needs. Resistance testing helps in determining the optimal treatment regimen. Treatment efficacy is monitored by the number of CD4⁺ cells and the amount of HIV in the blood.

Key Words

treatment of HIV - antiretroviral drugs - viral load - CD4⁺ cells - resistance

Literatur

• 1 Bartlett JA, DeMasi R, Quinn J. et al. . Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-a infected adults.  AIDS. 2001;  15 1369-1377
• 2 DeGruttola V, Dix L, Aáquila R. et al. . The relationship between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective studies using a standardized analysis plan.  Antiviral Therapy. 2000;  5 43-50
• 3 EuroGuidelines Group for HIV Resistance . Clinical and laboratory guidelines for the use of HIV-1 drug-resistance testing as part of treatment management: recommendations for the European setting. The EuroGuidelines Group for HIV resistance.  AIDS. 2001;  15 309-320
• 4 Gallant JE, Rodriguez A, Weinberg W. et al. .Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC + 3TC: ESS 30009 unplanned interim analysis. 43rd International conference on Antimicrobial Agents and Chemotherapy. Chicago 2003
• 5 Hammer SM, Vaida F, Bennett KK. et al. . Clinical Trials Group 398 Study Team: Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.  JAMA. 2002;  288 169-180
• 6 HIV-Journal, Sonderausgabe Medizin, Leitlinien für Diagnostik und Therapie: Deutsch-Österreichische Richtlinien zur antiretroviralen Therapie der HIV-Infektion. 2005: 7-20
• 7 Little SJ, Holte S, Routy JP. et al. . Antiretroviral-drug resistance among patients recently infected with HIV.  N Engl J Med. 2002;  347 385-394
• 8 Mellors JW, Munoz A, Giorgi JV. et al. . Plasma viral load and CD4⁺ lymphocytes as prognostic markers for HIV infection.  Ann Int Med. 1997;  126 946-954
• 9 Murphy RL, Brun S, Hicks C. et al. . ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.  AIDS. 2001;  15 F1-F9
• 10 Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2005
• 11 Rockstroh JK, Bergmann F, Wiesel W. et al. . Efficacy and safety of twice daily ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.  AIDS. 2000;  14 1181-1185
• 12 Staszewski S, Dauer B, von N Hentig. et al. . The LOPSAQ Study: 24 week analysis of the double protease inhibitor PI salvage regimen containing lopinavir (LPV/r) plus saquinavir (SQV) without any additional antiretroviral therapy (ART).  2nd IAS Conference Paris. 2003;  583
• 13 Stephan C, Hentig N, Kourbeti I. et al. . Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.  AIDS. 2004;  18 503-508
• 14 Staszewski S, Stephan C. State of the HAART. . Current strategies for antiretroviral therapy.  Internist. 2004;  45 1428-1436

Anschrift für die Verfasser